ADICET BIO, INC. Item 7.01 Regulation FD Disclosure
On
The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events
On
ADI-002 is an investigational allogeneic gamma delta CAR-T cell therapy developed and engineered by Adicet to express a GPC3-targeted CAR and a cell intrinsic soluble form of IL-15 designed to promote additional expansion and activity at the site of tumor engagement. It is the first of Adicet's product candidates designed specifically to target solid tumors.
Results presented at the SITC Annual Meeting detail findings from in vitro and in vivo preclinical evaluations of ADI-002. ADI-002 demonstrated expansion of gamma delta 1 T cells during manufacture with a predominant naïve-like phenotype. ADI-002 cells also demonstrated high expression of innate activating receptors, including NKG2D and DNAM-1, while maintaining a lower abundance of cells expressing exhaustion markers PD-1, LAG-3, TIGIT, and TIM-3.
In vitro, ADI-002 demonstrated potent and specific cytotoxicity against GPC3-positive cancer cell lines associated with high and low levels of target expression. The demonstrated in vitro killing activity of ADI-002 on cancer cells was associated with release of multiple effector cytokines. ADI-002 further demonstrated enhanced depth, duration and persistence of in vitro killing activity and was associated with increased proliferative potential.
In vivo, ADI-002 was evaluated in mice engrafted with human hepatocellular carcinoma tumors that naturally express GPC3. ADI-002 exhibited potent antitumor activity following a single dose without evident toxicities or graft versus host effects. Tissue-specific homing and proliferation of ADI-002 were compared to that of GPC3-targeted ?? CAR-T cells. ADI-002 cells specifically homed to, and proliferated within the tumors, whereas ?? CAR-T cells demonstrated high levels of off-target proliferation in mouse organ systems. These results demonstrate that, unlike ?? CAR-T cells, ADI-002 and the Company's gamma delta T cell platform achieved reduced alloreactive potential in these models without the need for manipulation of T cell receptors or incurring additional risks associated with genome editing. Together, Adicet believes these data support initial evaluation of safety and efficacy for ADI-002 in GPC3-positive malignancies.
The disclosure under this Item 8.01 contains "forward-looking statements" of
Adicet within the meaning of the Private Securities Litigation Reform Act of
1995 relating to business and operations of Adicet including, but not limited
to, the preclinical data resulting from early studies with ADI-002, including
future plans or expectations regarding the initiation, design, implementation,
timing, and success of future clinical studies of ADI-002 and expectations
regarding its other CAR gamma delta T cell therapy development activities; and
the therapeutic potential, safety and efficacy of ADI-002 for targeting solid
tumors. Any forward-looking statements in this press release are based on
management's current expectations and beliefs of future events, and are subject
to a number of risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements, including without limitation, the effect of COVID-19
on Adicet's business, including with respect to disruptions to preclinical and
clinical trials, business operations, and ability to raise additional capital;
Adicet's ability to execute on its strategy; that positive results from a
preclinical study may not necessarily be predictive of the results of future or
ongoing preclinical and clinical studies; future studies may fail to demonstrate
adequate safety and efficacy of our product candidates, which would prevent,
delay, or limit the scope of regulatory approval and commercialization; and
regulatory approval processes of the
--------------------------------------------------------------------------------
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit Number Description 99.1 Press release issued byAdicet Bio, Inc. onNovember 12, 2021 , furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).
--------------------------------------------------------------------------------
© Edgar Online, source
